Inulin Supplementation Does Not Reduce Plasma Trimethylamine N-Oxide Concentrations in Individuals at Risk for Type 2 Diabetes
Autor: | Cassie M Mitchell, Christopher J Angiletta, Andrew P. Neilson, Matthew W. Hulver, Kevin P. Davy, Mary Elizabeth Baugh, Brenda M. Davy, Cortney N. Steele |
---|---|
Přispěvatelé: | Food Science and Technology, Human Nutrition, Foods, and Exercise |
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty medicine.medical_treatment Inulin metabolite Trimethylamine Trimethylamine N-oxide lcsh:TX341-641 Type 2 diabetes prediabetes 030204 cardiovascular system & hematology Article 03 medical and health sciences chemistry.chemical_compound Methylamines 0302 clinical medicine Double-Blind Method Risk Factors Internal medicine medicine Choline Humans Aged 2. Zero hunger Meal 030109 nutrition & dietetics Nutrition and Dietetics Prebiotic cardiovascular Feeding Behavior Middle Aged medicine.disease 3. Good health Endocrinology Postprandial chemistry Diabetes Mellitus Type 2 Dietary Supplements prebiotic Female lcsh:Nutrition. Foods and food supply metabolism Food Science |
Zdroj: | Nutrients Volume 10 Issue 6 Nutrients, Vol 10, Iss 6, p 793 (2018) |
Popis: | Trimethylamine N-oxide (TMAO) is associated with type 2 diabetes (T2DM) and increased risk of adverse cardiovascular events. Prebiotic supplementation has been purported to reduce TMAO production, but whether prebiotics reduce fasting or postprandial TMAO levels is unclear. Sedentary, overweight/obese adults at risk for T2DM (n = 18) were randomized to consume a standardized diet (55% carbohydrate, 30% fat) with 10 g/day of either an inulin supplement or maltodextrin placebo for 6 weeks. Blood samples were obtained in the fasting state and hourly during a 4-h high-fat challenge meal (820 kcal 25% carbohydrate, 63% fat 317.4 mg choline, 62.5 mg betaine, 8.1 mg l-carnitine) before and after the diet. Plasma TMAO and trimethylamine (TMA) moieties (choline, l-carnitine, betaine, and &gamma butyrobetaine) were measured using isocratic ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). There were no differences in fasting or postprandial TMAO or TMA moieties between the inulin and placebo groups at baseline (all p > 0.05). There were no significant changes in fasting or postprandial plasma TMAO or TMA moiety concentrations following inulin or placebo. These findings suggest that inulin supplementation for 6 weeks did not reduce fasting or postprandial TMAO in individuals at risk for T2DM. Future studies are needed to identify efficacious interventions that reduce plasma TMAO concentrations. |
Databáze: | OpenAIRE |
Externí odkaz: |